[{"id":"43102ae6-d1ea-4271-9690-90fe3e1581ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731219","created_at":"2023-02-16T15:00:35.996Z","updated_at":"2024-07-02T16:35:55.393Z","phase":"Phase 1","brief_title":"UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05731219","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2025","study_completion_date":" 09/26/2025","last_update_posted":"2023-02-16"},{"id":"ecf3418c-bacc-4bfa-8dfc-631284d39661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722171","created_at":"2023-02-10T15:00:14.965Z","updated_at":"2024-07-02T16:35:55.834Z","phase":"Phase 1","brief_title":"Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05722171","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2023-02-10"}]